Tirzepatide

Mounjaro · Zepbound · LY3298176 · GIP/GLP-1 RA

"Semaglutide raised the bar. Tirzepatide raised it again. The first dual incretin agonist to hit 20% weight loss in a Phase III trial, while also outperforming semaglutide head-to-head. The science hasn't stopped moving."

Type

39 aa dual GLP-1/GIP agonist · single molecule

Half-life

~5 days · once-weekly SubQ

Status

UK: prescription only medicine (Mounjaro, Zepbound) · WADA: not specifically listed · US FDA: approved 2022 (T2D), 2023 (obesity), 2024 (OSA) · MHRA-licensed

Weight loss

20.9% body weight at 72 wks (SURMOUNT-1)

Protocol summary

Weight dose

2.5 → 15 mg/wk SubQ

T2D dose

2.5 → 15 mg/wk SubQ

Titration

~20 weeks to maintenance

Clinical-labelled

Mounjaro (T2D) / Zepbound (obesity): 2.5 → 15 mg/wk SubQ · weekly titration

UK access via NHS or licensed private prescriber; do not use unverified compounded versions

How we read the evidence

GIP/GLP-1 dual agonist · FDA-approved as Mounjaro (T2D 2022) and Zepbound (obesity 2023) · 20.9% mean weight loss in SURMOUNT-1 · superior to semaglutide in head-to-head SURMOUNT-5 · the current standard for weight-loss pharmacotherapy

Animal evidence

Substantial preclinical foundation. Tirzepatide is a single 39-amino-acid synthetic peptide that simultaneously activates two incretin receptors: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The molecule incorporates a fatty acid moiety enabling albumin binding for half-life extension to ~5 days, supporting weekly dosing. Mechanism rationale: dual GIP/GLP-1 agonism produces synergistic effects on appetite, energy intake, and metabolic function beyond what GLP-1 monotherapy achieves — GIP provides additional insulinotropic effect and may modulate adipose tissue handling. Decades of incretin biology preceded the specific compound development by Eli Lilly.

Community & clinical practice

Standard dosing follows the same titration framework for both indications. Start at 2.5 mg weekly for 4 weeks (initiation, not therapeutic), then escalate to 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg as tolerated, with at least 4 weeks at each step before escalation. Most users land at 10–15 mg/week for weight management, often lower for T2D where 5–10 mg achieves glycaemic targets. Titration is for GI tolerance — nausea, vomiting, constipation, occasional diarrhoea most common in escalation phase. Long-term continuous use is the standard model; discontinuation typically causes weight regain. Compounded versions exist where pharmacy-grade access is restricted or expensive; quality and authenticity vary. Compounded versions face FDA regulatory scrutiny as the shortage that previously permitted compounding has been resolved.

Human trial data

Extensive Phase 3 evidence base — SURMOUNT program. SURMOUNT-1 (NCT04184622, 72 weeks) — adults without diabetes: mean weight loss 15.0% (5 mg), 19.5% (10 mg), 20.9% (15 mg) vs 3.1% placebo. SURMOUNT-3 (NCT04657016, 72 weeks) — after intensive lifestyle intervention: additional −18.4% with tirzepatide vs +2.5% placebo (treatment difference −20.8 percentage points), 87.5% achieving additional ≥5% weight reduction vs 16.5% placebo. SURMOUNT-5 (NCT05822830, 72 weeks, head-to-head with injectable semaglutide 2.4 mg): tirzepatide produced 20.2% weight loss vs semaglutide's 13.7% — first major head-to-head comparison. SURMOUNT-OSA: significant reduction in obstructive sleep apnoea breathing disruptions, supporting the OSA indication. SURPASS T2D program supported the diabetes approval. Most adverse events were mild-to-moderate GI.

Regulatory status

FDA-approved as Mounjaro (T2D) in May 2022 and as Zepbound (chronic weight management) in November 2023. EMA, MHRA, and Japanese PMDA approved across both indications. November 2024 OSA indication added based on SURMOUNT-OSA. FDA approved a 4-dose KwikPen presentation in 2026 consolidating one month of therapy into one device. Boxed warning (class effect): thyroid C-cell tumour risk based on rodent data — contraindicated in personal/family history of medullary thyroid carcinoma or MEN-2. Other safety signals: pancreatitis, gallbladder disease, hypoglycaemia (with insulin/sulfonylureas), acute kidney injury from GI dehydration. WADA does not list tirzepatide specifically.

Convergence

Tirzepatide is the current standard for weight-loss pharmacotherapy — head-to-head superior to semaglutide in SURMOUNT-5 (20.2% vs 13.7%), broad FDA-approved indication set (T2D, obesity, OSA), and dose-response data extending to 15 mg/week. Standard protocol: titrate from 2.5 mg over 16+ weeks to 10–15 mg/week SubQ, long-term continuous use, plan for weight regain on discontinuation. Pep IQ flags this honestly: this is the current best-evidenced GLP-1-class therapy for weight loss, with the largest effect size of any approved compound. The newer triple agonist retatrutide produces somewhat larger effects in Phase 2 but is not yet approved. Tirzepatide is the right starting choice for most cases requiring incretin-based therapy in 2026.

Origin & Background

Dual incretin — the next generation

Tirzepatide is a first-in-class dual agonist of both GLP-1 receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors — two complementary incretin hormones released from the gut after eating. Developed by Eli Lilly, it was engineered as a single molecule that activates both receptor systems simultaneously, producing greater metabolic benefits than a pure GLP-1 agonist like semaglutide through synergistic mechanisms.

It was approved by the FDA in May 2022 as Mounjaro for type 2 diabetes, and in November 2023 as Zepbound for chronic weight management — the first dual incretin obesity drug approved. The SURMOUNT-5 trial (2025, NEJM) was the decisive head-to-head comparison: tirzepatide produced 20.2% mean weight loss vs semaglutide's 13.7% at 72 weeks — a statistically significant and clinically substantial difference.

Why dual agonism produces more weight loss: GIP and GLP-1 work through complementary pathways. GLP-1 reduces appetite centrally and slows gastric emptying. GIP additionally acts on adipose tissue (reducing fat storage), the brain (enhancing satiety signalling beyond GLP-1 alone), and the pancreas (amplifying insulin response). The combination of both signals is additive in a way that a single receptor cannot replicate. This is not simply a higher dose of semaglutide — it is a mechanistically different intervention.

Science & Mechanism

Two incretins, one molecule

Mechanism of Action

GLP-1R activation: Activates GLP-1 receptors in the hypothalamus (appetite suppression), gut (delayed emptying), and pancreas (glucose-dependent insulin secretion). Identical pathway to semaglutide but as one component of a dual signal.

GIPR activation: GIP receptors are expressed in adipose tissue, the brain, bone, and pancreas. GIPR activation reduces fat storage, enhances GLP-1-mediated satiety signalling in the brain, and increases insulin secretion synergistically with GLP-1R activation. This is the additional mechanism that semaglutide lacks.

Greater satiety signalling: The dual receptor activation produces stronger and more sustained satiety signals than GLP-1 alone. This translates to greater appetite reduction and lower caloric intake, driving the superior weight loss versus semaglutide.

Improved glycaemic control: The combined GLP-1/GIP insulin secretion mechanism produces superior HbA1c reductions compared to semaglutide in head-to-head T2D trials (SURPASS programme).

Cardiovascular and metabolic effects: SURPASS-CVOT established cardiovascular non-inferiority vs dulaglutide. SURMOUNT-5 post-hoc analysis showed significantly greater predicted 10-year CVD risk reduction with tirzepatide vs semaglutide (2.4% vs 1.4% absolute reduction). However, semaglutide retains stronger direct MACE outcome data from the SELECT trial.

The SURMOUNT trial programme established tirzepatide's superiority for weight loss. SURMOUNT-1 showed 20.9% weight loss at the highest dose. SURMOUNT-5 (2025 NEJM) — the first head-to-head trial — showed tirzepatide's 20.2% vs semaglutide's 13.7% at 72 weeks, with 31.6% of tirzepatide patients achieving 25%+ weight loss vs 16.1% for semaglutide. By 2026, the TRIUMPH programme is expected to deliver further cardiovascular outcomes data that may close the gap between tirzepatide and semaglutide's cardiovascular evidence.

Benefits & Evidence

What the data shows

⚖️

Weight loss — class-leading

SURMOUNT-1: up to 20.9% body weight reduction. SURMOUNT-5 head-to-head vs semaglutide: 20.2% vs 13.7% at 72 weeks (P<0.001). 31.6% of patients achieved ≥25% weight loss. The best weight loss data for any approved anti-obesity medication.

● Strong — multiple Phase III RCTs · FDA approved

🩸

Glycaemic control (T2D)

SURPASS programme: HbA1c reductions of 1.8–2.1% across multiple trials, superior to semaglutide in head-to-head T2D comparisons. Approved for type 2 diabetes management.

● Strong — Phase III RCTs · FDA approved

🫀

Cardiovascular risk factor reduction

SURMOUNT-5 post-hoc: greater predicted 10-year CVD risk reduction vs semaglutide (2.4% vs 1.4%). SURPASS-CVOT: cardiovascular non-inferiority. Direct MACE outcome data awaited from TRIUMPH programme (results expected 2026–2027).

● Moderate — risk factor data strong · MACE outcomes pending

🫁

HFpEF and MASH (liver disease)

Significant improvements in heart failure with preserved ejection fraction (SUMMIT trial). FDA Breakthrough Therapy designation for MASH (metabolic dysfunction-associated steatohepatitis) — Phase III SYNERGY data promising.

● Moderate — dedicated trials

🦴

Sleep apnoea

FDA approved tirzepatide for obstructive sleep apnoea (OSA) in obesity in 2024 — the first pharmacological treatment for this condition. Significant AHI reductions in both PAP-treated and PAP-untreated patients.

● Strong — FDA approved indication

Things to know

Risks & considerations

Moderate

GI side effects — nausea, diarrhoea, constipation, vomiting. Similar profile to semaglutide. Evening injection helps. Slow titration is essential — standard schedule goes over 20+ weeks.

Moderate

Muscle mass loss — greater appetite suppression means greater risk of inadequate protein intake. At 20% weight loss, lean mass preservation requires active effort. Resistance training + high protein is not optional.

Moderate

Nutrient depletion — same as semaglutide: B12, magnesium, calcium require supplementation throughout treatment.

Serious

Thyroid C-cell tumours — same black box warning as all GLP-1 agonists. Contraindicated in medullary thyroid cancer or MEN-2 history.

Serious

Pancreatitis — rare but reported. History of pancreatitis is a relative contraindication.

⚠ Key Warnings

Tirzepatide's superior weight loss makes muscle preservation even more critical than with semaglutide. 20% body weight loss without resistance training will include significant lean mass loss.

The cardiovascular outcome evidence is currently less mature than semaglutide's. For patients with established CVD, semaglutide currently has stronger direct MACE outcome data. This may change with TRIUMPH results.

Mounjaro (T2D) and Zepbound (obesity) are different brand names for the same molecule at different approved doses/indications. Using Mounjaro off-label for weight loss in non-diabetic patients is common but should be under physician guidance.

Compounded tirzepatide: the FDA has warned strongly against compounded versions. Tirzepatide is not and was not on the FDA drug shortage list at the time compounding became widespread — many compounded products may be of uncertain quality.